Regeneron's Eylea snags prefilled syringe approval as Novartis rival looms

Regeneron
Regeneron's Eylea scored a nod for a prefilled injector application to treat four retinal conditions. (Regeneron)

Eye med Eylea has been a blockbuster sales force for Regeneron, but Novartis’ challenger brolucizumab is on the horizon. Could a new delivery option give Eylea a leg up?

That's what Regeneron's hoping. The FDA Tuesday approved a new prefilled injector for 2-milligram single doses of Eylea to treat patients with wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.

The drugmaker touted the new approval as a game-changer for physicians, taking multiple preparation steps out of the original vial dose regimen. Eylea is now the only drug approved to treat four retinal diseases with a single-dose prefilled injector, although Roche's Lucentis has two prefilled injector doses that cover all four of those indications separately. 

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

Wednesday, July 8, 2020 | 11am EST / 8am PST

This webinar will describe strategies to mitigate risks, reduce attrition and help improve the quality and safety of your drug candidate.

Regeneron is hoping the newest green light will help it secure its place as the top-performing wet AMD drug on the market as competitors loom.

RELATED: Regeneron's Eylea pads its armor with diabetic retinopathy approval

Suggested Articles

Johnson & Johnson will shell out at least $480 million to Emergent BioSolutions to produce millions of doses of its COVID-19 vaccine hopeful.

Despite the many HIV drugs available, some patients still can’t be successfully treated because they're drug-resistant. Now, they have a new option.

Sanofi and Regeneron have stopped their U.S. trial for Kevzara in COVID-19 after the drug showed no benefit in treating ventilated patients.